Where discoveries are delivered.℠

External Resources:

Dr. Nathan Painter

Family Medicine

Nathan A. Painter

Nathan A. Painter, Pharm.D., CDE

Health Sciences Associate Clinical Professor
Skaggs School of Pharmacy and Pharmaceutical Sciences


(858) 822-3487

Research Summary: Family Medicine

Dr. Painter is currently involved in researching the impact of pharmacists and pharmacy students to enable seniors who were enrolled in a Part D plan to select a PDP that minimized their out-of-pocket expenditures and whether and to what extent student pharmacists’ interventions reduce out-of-pocket PDP costs for Medicare beneficiaries.

Dr. Painter’s research areas of focus include measuring the impact of pharmacist interventions in diabetes, hypertension, hyperlipidemia, collaborative care, and safe medication usage in patient populations.

Dr. Painter joined the faculty at the UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences in September 2009 where he will be teaching in the Pharmacy Practice courses and is co-director of clinical pharmacy services at UCSD Family Medicine Clinics. 

Academic Achievements


Completion of pre-pharmacy requirements from Old Dominion University 1999; Pharm.D. from Virginia Commonwealth University (VCU) 2003; ASHP Ambulatory Care Residency in Cardiovascular Risk Reduction at VCU 2004; Certified in Immunization Delivery 2001, Certified Diabetes Educator 2007, Certified in Pharmaceutical Care for Patients with Diabetes 2007 

Awards and Honors:

Phi Lambda Sigma, NCLAM 2011, UCSD WOW Factor, UCSD Pharmacy Week Certificate of Recognition. 

Leadership Experience:

President, Southern California College of Clinical Pharmacy; First ambulatory care pharmacist at Loma Linda University to establish a collaborative practice agreement with physicians with prescribing authority. 


  • Pharmacy Practice (SPPS 201, 202, 203)
  • Medicare Part D Outreach Elective (SPPS 272)
  • Prescription Drug Abuse Elective (SPPS 279)

Key Contributions to Pharmaceutical Sciences

  • Established role of ambulatory care/family medicine pharmacist.
  • Effective use of medications in family medicine patients.
  • Development and expansion of family medicine clerkships for pharmacy students.

Selected Recent Publications (view more)

  • Painter et al. (2006) New and Standard Treatment Options for Type 2 Diabetes. Diabetic Microvascular Complications Today. 3:40-47.
  • Painter NA et al. (2007). New treatment options for persons with diabetes. Drug Benefit Trends. 19 (Supplement B):10-14.
  • Painter NA et al. (2007). Clinical significance, insulin and drugs used for the treatment of diabetes in Foye's Principles of Medicinal Chemistry. 6th edition. Lippincott Williams & Wilkins, Baltimore.
  • Lawlor MT et al. (2008). AADE Position Statement: Management of children with diabetes in the school setting. Diabetes Educ. 34:439-443.
  • Painter NA (2012). Clinical Significance and Clinical Scenario, Insulin and Drugs Used to Treat Diabetes in Foye's Principles of Medicinal Chemistry. 7thedition. Lippincott Williams & Wilkins, Baltimore.
  • Painter NA (2012). Providing positive impacts in varied settings. California Pharmacist. 59:12-15.
  • Painter NA, et al. (2013). An Evidence-Based and Practical Approach to Using Bydureon in Patients with Type 2 Diabetes. J Am Board Fam Med; 26:203–210.

Potential Collaborative Programs with the Pharmaceutical Industry

  • Evaluation of Medicare Part D cost savings.

  • Developing guidelines for the use of diabetes and cardiovascular medications.

  • Developing educational workshops for diabetes and cardiovascular disease patients.

  • Assessing impact of collaborative care on patient outcomes.

  • Developing service interventions that will improve clinical outcomes for patients with diabetes, hypertension, hyperlipidemia, asthma, and other chronic diseases